| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 21 | 34.9x | 17.3x | Bottom tier | |
Growth | 36 | 8.6% | 7.1% | Bottom tier | |
Quality | 72 | 13.2% | 4.4% | Top tier | |
Safety | 69 | 1.2x | 2.6x | Top tier | |
Capital Return | 67 | 0.57% | 0.06% | Top tier | |
Momentum | 95 | 17.2% | -1.7% | Top tier | |
Sentiment | 63 | 11 | 3 | Around median |
The floor: what the company is worth if growth stopped today
77% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 5.00% as of 2026-10-23. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Agilent Technologies operates in scientific instruments and analytical and diagnostic laboratory solutions, generating revenue from the sale of analytical instruments, consumables, and after-sales services, in addition to specialized contract development and manufacturing services. Its business drivers include liquid and gas chromatography instruments, spectroscopy platforms, pathology, companion diagnostics, and genomics solutions, while the Agilent CrossLab segment converts the installed instrument base into recurring maintenance and consumables revenue after the warranty period, which typically lasts 12 months.
In Q3 fiscal 2026, revenue reached $1.88 billion, with reported growth of 8.1% and core constant-currency growth of 7.3%. Life Sciences and Diagnostics Markets grew 10%, Applied Markets grew 7%, and Agilent CrossLab grew more than 5%; the pharmaceutical business also grew 12%, China 9%, and the Americas 10%. According to EDGAR data, gross profit was approximately $1.0 billion, net income was $362 million, and GAAP earnings per share were $1.28.
Non-GAAP gross margin was 56.4%, but was 54.9% excluding a net benefit from tariff refunds, while operating margin was 28.3%, or 27.2% excluding that benefit. Adjusted earnings per share rose to $1.62, supported by $0.06 from the refunds, and were $1.56 without them, representing 14% year-over-year growth. The quarter generated $519 million in operating cash flow and $439 million in free cash flow, with a net leverage ratio of one time.
The analyst consensus is “Buy,” with an average target of $170 and a wide range between $150 and $185; the average is approximately 3.8% above the 52-week range high of $163.75, while the lowest target is approximately 8.4% below it. Barclays raised its target on August 27, 2026, from $150 to $175 following the Q3 fiscal 2026 results, but the absence of an available price-to-earnings ratio and the wide target range require linking the valuation to Agilent's ability to achieve fiscal 2026 growth of 5.8% to 6.0% and maintain margin expansion after the tariff refund benefit ends.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
Revenue reached $1.88 billion, with reported growth of 8.1% and core constant-currency growth of 7.3%. EDGAR data showed gross profit of approximately $1.0 billion, net income of $362 million, and GAAP earnings per share of $1.28. Adjusted earnings per share were $1.62, including a $0.06 benefit from tariff refunds, versus $1.56 excluding them. Operating margin also reached 28.3%, or 27.2% excluding the impact of the refunds.
The company expects annual reported revenue of between $7.49 billion and $7.51 billion and core constant-currency growth of between 5.8% and 6.0%. It expects earnings per share of between $6.18 and $6.21, including tariff refunds, or between $6.12 and $6.15 excluding them. For Q4 fiscal 2026, it expects revenue of between $1.98 billion and $2 billion and earnings per share of between $1.71 and $1.74. The outlook for that quarter does not include any future benefit from tariff refunds.
Shipments of the 9500 Triple Quad ICP-MS began in late July 2026, and its potential sales pipeline exceeded $60 million, with strong demand from semiconductor supply-chain customers. Shipments of the 8890B and 8860B systems began in July 2026, and orders during their first two months exceeded expectations by more than double. The number of new accounts adopting Altura columns for biopharmaceuticals also increased 28% quarter over quarter. Infinity III LC continued to support low-double-digit growth in liquid chromatography instrument revenue.
Automated analysis for informational purposes only — not investment advice.
The company completed the mechanical work on the Train C facility and expects it to begin generating revenue in the spring following the August 26, 2026 call. 75% of the capacity available for fiscal 2027 was booked through purchase orders, with full capacity expected to be reached gradually over six to eight quarters. Advanced Therapeutics, which includes the NASD and BIOVECTRA operations, grew approximately 30% in Q3 fiscal 2026. However, the company expects growth in this business to be flat in Q4 due to a year-over-year comparison exceeding 40% and the timing of regulatory responses related to customer programs.
Revenue in China grew 9% in Q3 fiscal 2026 versus management's previous expectation of flat performance, supported by double-digit growth in pharmaceuticals and food. The company recorded gains at two leading contract research and manufacturing organizations and won a PFAS project at a commercial testing laboratory, while demand for the 9500 also emerged from semiconductor customers. In pharmaceutical reshoring, Agilent received orders from five of the world's ten largest pharmaceutical companies during the same quarter. Management estimated the industry opportunity at approximately $1 billion through 2030, and Agilent aims to capture at least one-third of it, with revenue contributions beginning in fiscal 2027.
The first risk is Advanced Therapeutics slowing to flat growth in Q4 fiscal 2026 after approximately 30% in the previous quarter, alongside regulatory timelines related to customer programs. The second is pressure from higher material costs and the supply chain, in addition to Q3 margin benefiting by approximately 110 basis points from tariff refunds that are not included in the following quarter's outlook. Performance also remained uneven, with academia and government declining 3% and Europe growing only 2%. Finally, China represents approximately 20% of revenue, making the sustainability of its 9% growth an important factor in achieving the annual outlook.